Cardiff Oncology, Inc. $CRDF Shares Newly Acquired by GoalVest Advisory LLC

GoalVest Advisory LLC bought a new position in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) during the 3rd quarter, Holdings Channel reports. The institutional investor bought 687,285 shares of the company’s stock, valued at approximately $832,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in Cardiff Oncology in the second quarter valued at approximately $1,265,000. Flputnam Investment Management Co. acquired a new stake in Cardiff Oncology during the second quarter worth approximately $322,000. X Square Capital LLC purchased a new stake in shares of Cardiff Oncology during the 2nd quarter worth approximately $267,000. GSA Capital Partners LLP acquired a new position in shares of Cardiff Oncology in the 2nd quarter valued at $225,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Cardiff Oncology in the 2nd quarter valued at $210,000. Hedge funds and other institutional investors own 16.29% of the company’s stock.

Cardiff Oncology Stock Performance

Cardiff Oncology stock traded down $0.06 during midday trading on Friday, hitting $1.12. 226,864 shares of the company’s stock were exchanged, compared to its average volume of 1,121,609. The stock has a market cap of $87.51 million, a price-to-earnings ratio of -1.87 and a beta of 1.42. Cardiff Oncology, Inc. has a 12-month low of $0.76 and a 12-month high of $3.31. The firm’s 50 day simple moving average is $1.06 and its 200 day simple moving average is $1.36.

Cardiff Oncology (NASDAQ:CRDF) last announced its earnings results on Tuesday, August 11th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). Cardiff Oncology had a negative net margin of 7,885.43% and a negative return on equity of 103.10%. The business had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.06 million. On average, equities research analysts forecast that Cardiff Oncology, Inc. will post -0.6 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on CRDF shares. Wall Street Zen raised shares of Cardiff Oncology from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 5th. HC Wainwright upgraded Cardiff Oncology from a “neutral” rating to a “buy” rating in a research report on Tuesday, September 15th. William Blair downgraded Cardiff Oncology from an “outperform” rating to a “market perform” rating in a report on Tuesday, August 11th. Finally, Weiss Ratings downgraded Cardiff Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 22nd. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $7.50.

Cardiff Oncology Profile

Cardiff Oncology, Inc is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company’s lead investigational product is onvansertib, an oral, highly selective inhibitor of polo-like kinase 1 (PLK1), an enzyme involved in cell division and cancer-cell growth.

Cardiff Oncology has primarily studied onvansertib in combination with existing treatments for patients with difficult-to-treat solid tumors, including KRAS-mutated metastatic colorectal cancer.